Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Outpatient parenteral antimicrobial therapy for the treatment of methicillin-susceptible Staphylococcus aureus: a comparison of cefazolin and ceftriaxone.

Winans SA, Luce AM, Hasbun R.

Infection. 2013 Aug;41(4):769-74. doi: 10.1007/s15010-013-0477-0. Epub 2013 May 19.

PMID:
23686435
2.

Comparative outcomes of β-lactam antibiotics in outpatient parenteral antibiotic therapy: treatment success, readmissions and antibiotic switches.

Lee B, Tam I, Weigel B 4th, Breeze JL, Paulus JK, Nelson J, Allison GM.

J Antimicrob Chemother. 2015 Aug;70(8):2389-96. doi: 10.1093/jac/dkv130. Epub 2015 May 29.

3.

Outcomes of ceftriaxone use compared to standard of therapy in methicillin susceptible staphylococcal aureus (MSSA) bloodstream infections.

Patel UC, McKissic EL, Kasper D, Lentino JR, Pachucki CT, Lee T, Lopansri BK.

Int J Clin Pharm. 2014 Dec;36(6):1282-9. doi: 10.1007/s11096-014-9999-5. Epub 2014 Sep 4.

PMID:
25186790
4.

A retrospective comparison of ceftriaxone versus oxacillin for osteoarticular infections due to methicillin-susceptible Staphylococcus aureus.

Wieland BW, Marcantoni JR, Bommarito KM, Warren DK, Marschall J.

Clin Infect Dis. 2012 Mar 1;54(5):585-90. doi: 10.1093/cid/cir857. Epub 2011 Dec 5.

5.

Comparative evaluation of the tolerability of cefazolin and nafcillin for treatment of methicillin-susceptible Staphylococcus aureus infections in the outpatient setting.

Youngster I, Shenoy ES, Hooper DC, Nelson SB.

Clin Infect Dis. 2014 Aug 1;59(3):369-75. doi: 10.1093/cid/ciu301. Epub 2014 Apr 29.

6.

Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia.

Schweizer ML, Furuno JP, Harris AD, Johnson JK, Shardell MD, McGregor JC, Thom KA, Cosgrove SE, Sakoulas G, Perencevich EN.

BMC Infect Dis. 2011 Oct 19;11:279. doi: 10.1186/1471-2334-11-279.

7.

β-Lactam Therapy for Methicillin-Susceptible Staphylococcus aureus Bacteremia: A Comparative Review of Cefazolin versus Antistaphylococcal Penicillins.

Li J, Echevarria KL, Traugott KA.

Pharmacotherapy. 2017 Mar;37(3):346-360. doi: 10.1002/phar.1892. Epub 2017 Feb 7. Review.

PMID:
28035690
8.
9.

Comparison of cefazolin versus oxacillin for treatment of complicated bacteremia caused by methicillin-susceptible Staphylococcus aureus.

Li J, Echevarria KL, Hughes DW, Cadena JA, Bowling JE, Lewis JS 2nd.

Antimicrob Agents Chemother. 2014 Sep;58(9):5117-24. doi: 10.1128/AAC.02800-14. Epub 2014 Jun 16.

10.

Outcomes of osteomyelitis among patients treated with outpatient parenteral antimicrobial therapy.

Tice AD, Hoaglund PA, Shoultz DA.

Am J Med. 2003 Jun 15;114(9):723-8.

PMID:
12829198
11.

Implementation of a cefazolin-based stewardship pathway for methicillin-susceptible Staphylococcus aureus bloodstream infections paired with infectious diseases consultation.

Lee BJ, Rao SN, Wang SK, Lee JY, Lakada IY, Gilbert EM, Barr VO, Postelnick MJ, Sutton SH, Zembower TR, Bolon M, Scheetz MH, Rhodes NJ.

Int J Antimicrob Agents. 2017 May;49(5):650-654. doi: 10.1016/j.ijantimicag.2016.12.021. Epub 2017 Mar 6.

PMID:
28279787
12.

Treatment outcomes with cefazolin versus oxacillin for deep-seated methicillin-susceptible Staphylococcus aureus bloodstream infections.

Rao SN, Rhodes NJ, Lee BJ, Scheetz MH, Hanson AP, Segreti J, Crank CW, Wang SK.

Antimicrob Agents Chemother. 2015 Sep;59(9):5232-8. doi: 10.1128/AAC.04677-14. Epub 2015 Jun 15. Erratum in: Antimicrob Agents Chemother. 2015 Nov;59(11):7159.

13.

Continuous cefazolin infusion to treat bone and joint infections: clinical efficacy, feasibility, safety, and serum and bone concentrations.

Zeller V, Durand F, Kitzis MD, Lhotellier L, Ziza JM, Mamoudy P, Desplaces N.

Antimicrob Agents Chemother. 2009 Mar;53(3):883-7. doi: 10.1128/AAC.00389-08. Epub 2008 Dec 15.

14.

Cefazolin versus Nafcillin for Methicillin-Sensitive Staphylococcus aureus Bloodstream Infection in a California Tertiary Medical Center.

Pollett S, Baxi SM, Rutherford GW, Doernberg SB, Bacchetti P, Chambers HF.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):4684-9. doi: 10.1128/AAC.00243-16. Print 2016 Aug.

15.

Pharmacodynamic profile of commonly utilised parenteral therapies against meticillin-susceptible and meticillin-resistant Staphylococcus aureus collected from US hospitals.

Housman ST, Sutherland CA, Nicolau DP.

Int J Antimicrob Agents. 2014 Sep;44(3):235-41. doi: 10.1016/j.ijantimicag.2014.05.012. Epub 2014 Jun 24.

PMID:
25052866
16.

High-dose cefazolin on consecutive hemodialysis in anuric patients with Staphylococcal bacteremia.

Renaud CJ, Lin X, Subramanian S, Fisher DA.

Hemodial Int. 2011 Jan;15(1):63-8. doi: 10.1111/j.1542-4758.2010.00507.x. Epub 2010 Nov 24.

PMID:
21105995
17.

Outpatient parenteral antimicrobial therapy (OPAT) in a teaching hospital-based practice: a retrospective cohort study describing experience and evolution over 10 years.

Barr DA, Semple L, Seaton RA.

Int J Antimicrob Agents. 2012 May;39(5):407-13. doi: 10.1016/j.ijantimicag.2012.01.016. Epub 2012 Mar 23.

PMID:
22445493
18.

The outcome of prophylactic intravenous cefazolin and ceftriaxone in cirrhotic patients at different clinical stages of disease after endoscopic interventions for acute variceal hemorrhage.

Wu CK, Wang JH, Lee CH, Wu KL, Tai WC, Lu SN, Hu TH, Chuah SK.

PLoS One. 2013 Apr 22;8(4):e61666. doi: 10.1371/journal.pone.0061666. Print 2013.

19.

Characteristics and outcomes of outpatient parenteral antimicrobial therapy at an academic children's hospital.

Madigan T, Banerjee R.

Pediatr Infect Dis J. 2013 Apr;32(4):346-9. doi: 10.1097/INF.0b013e31827ee1c2.

PMID:
23249915
20.

Comparative effectiveness of beta-lactams versus vancomycin for treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections among 122 hospitals.

McDanel JS, Perencevich EN, Diekema DJ, Herwaldt LA, Smith TC, Chrischilles EA, Dawson JD, Jiang L, Goto M, Schweizer ML.

Clin Infect Dis. 2015 Aug 1;61(3):361-7. doi: 10.1093/cid/civ308. Epub 2015 Apr 21.

PMID:
25900170

Supplemental Content

Support Center